Question · asked by 1 review

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy: Adverse events: hypertension

Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy
Specific adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic… (2021) · Cochrane Headline outcomes only
RR 5.14 [1.28, 20.73]1 study · 52 participantsLow

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
2021 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.